Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 November 2019 | Story Valentino Ndaba | Photo Igno van Niekerk
Rees Mann
Two days before International Men’s Day Rees Mann addressed Kovsies about their responsibility to fight against abuse and rape.

“Half-a-million men commit suicide every year across the world. Men in South Africa are four times more likely to commit suicide than women but we are not talking about it. We try to forget that it exists because we want to assume the role of what society says masculinity should be.” 

Rees Mann, ambassador at the South African Male Survivor of Sexual Abuse (SAMSOSA), made this shocking yet true statement at the first-ever Men’s Breakfast hosted by the University of the Free State (UFS) on 17 November 2019. Mann shared his story of surviving rape and abuse with 140 other men on the Bloemfontein Campus.

The Breakfast took place just days before the 16 Days of Activism for No Violence against Women and Children, a time when the nation will be on a drive to further awareness efforts around the issue.

Redefining masculinity and defying toxic masculinity

As a sexual assault survivor, Mann demonstrated what it looks like to lead by example in breaking the silence. “I still suffer from the consequences of being abused and raped. I have semi-facial dystonia, posttraumatic stress disorder, bipolar and Adult Attention Deficit Hyperactivity Disorder but I manage each one of these issues. I am stronger than any other male who suffers in silence instead of seeing a psychologist.”

 “The sad reality is that when a male commits suicide everybody around him says ‘I didn’t know he was so depressed’ because mental health issues for us males are considered a weakness,” said Mann. 

Having walked the walk, Mann believes that seeking help is a sign of strength. “It is time for us men to take a stand and define our own masculinity,” he added.

Ending a vicious cycle
 

Mann pleaded with Kovsie men to join in the fight against the cycle of violence in South Africa. His fear is that if men do not heal themselves and introspect, the cycle of violence and gender-based violence will continue in this country. “Hurt people hurt people. Toxic masculinity kills not only me but women and children too.”

While debunking the myth surrounding rape victims always transforming into rapists, he acknowledged there is a percentage of males who were raped and abused who go on to become rapists and abusers. However, there are also perpetrators who were never sexually assaulted. The onus, according to Mann, is on all males to fight against these crimes to prevent history from repeating itself, in turn making South Africa a safer space for all who live in it.

Why these conversations are critical

Lemena Thebe, a senior officer at Student Academic Services who attended the Men’s Breakfast, was of the view that dialogue is an essential part of the process in the fight against rape, abuse and violence.

“I realised that we as men need to speak out about our challenges. Whether we were victims as boys or suffered any type of abuse as adults, we don’t have to be ashamed,” said Thebe.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept